In a recent study published in Frontiers in Medicine, researchers showed that “almost 90% of patients with dementia suffer from some type of neurobehavioral symptom, and there are no approved medications to address these symptoms.” Neuropsychiatric symptoms (NPS) occur in up to 90% of patients with dementia and are associated with a reduced quality of life, according
In a recent study published in Frontiers in Medicine, researchers showed that “almost 90% of patients with dementia suffer from some type of neurobehavioral symptom, and there are no approved medications to address these symptoms.”
Neuropsychiatric symptoms (NPS) occur in up to 90% of patients with dementia and are associated with a reduced quality of life, according to the study and is
characterized by a progressive decline in “cognitive and functional abilities and challenging behavioral symptoms, is one of the major causes of disability and dependency among older adults.”
Cannabis Treatment
The clinical trial aims to evaluate the “safety and efficacy of the medical cannabis oil “Avidekel” for the reduction of behavioral disturbances among patients with dementia.”
Results
“There was a statistically significant difference in the proportion of subjects who had a Cohen-Mansfield Agitation Inventory score reduction of ≥ 4 points at week 16: 24/40 (60.0%) and 6/20 (30.0%) for investigational and control groups, respectively,” reads the clinical trial.
Read the story at Benzinga
